v3.25.1
REVENUES
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES REVENUES
The Company’s revenues by segment and by payers/customer groups were as follows:
Three Months Ended March 31, 2025Three Months Ended March 31, 2024
North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotal
Payer/Customer
Dx
   Clients24 %— %— %24 %25 %— %— %25 %
   Patients10 %— %— %10 %10 %— %— %10 %
   Medicare and Medicaid8 %— %— %8 %8 %— %— %8 %
   Third party36 %— %— %36 %35 %— %— %35 %
Total Dx revenues by payer78 %— %— %78 %78 %— %— %78 %
BLS
Pharmaceutical, biotechnology, and medical device companies9 %9 %4 %22 %9 %9 %4 %22 %
Total Revenues
87 %9 %4 %100 %87 %9 %4 %100 %
Revenues in the United States (U.S.) were $2,813.8 (84.1%) and $2,654.6 (83.6%) for the three months ended March 31, 2025, and 2024, respectively.
Accounts Receivable, Unbilled Services, and Unearned Revenue
The following table provides information about accounts receivable, unbilled services, and unearned revenue from contracts with customers:
March 31, 2025December 31, 2024
Dx accounts receivable$1,403.2 $1,259.3 
BLS accounts receivable758.6 729.5 
Less BLS allowance for credit losses(38.6)(44.7)
Accounts receivable, net$2,123.2 $1,944.1 
Gross unbilled services$158.8 $160.5 
Less reserve for unbilled services(7.5)(7.6)
Unbilled services$151.3 $152.9 
Revenues recognized during the period that were included in the unearned revenue balance at the beginning of the period were $68.9 and $51.0 for the three months ended March 31, 2025, and 2024, respectively.
Allowance for Credit Losses
BLS estimates future expected credit losses on accounts receivable and unbilled services over the remaining collection period of the instrument. The rollforward for the allowance for credit losses is as follows:
Accounts ReceivableUnbilled ServicesTotal
Allowance for credit losses at December 31, 2024$44.7 $7.6 $52.3 
Write offs(6.8)(0.2)(7.0)
Foreign currency impact
0.7 0.1 0.8 
Allowance for credit losses at March 31, 2025$38.6 $7.5 $46.1